Anlotinib as maintenance therapy for high-risk rhabdomyosarcoma in children
Part of Cancer clinical trials.
This trial tests whether taking anlotinib (a targeted therapy that may help stop cancer growth) after first-line treatment reduces the chance of rhabdomyosarcoma coming back in children with high-risk or intermediate-risk disease. Your child may be eligible if they've achieved complete remission and meet specific health and lab criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 5 and 18 years old
- Have high-risk or intermediate-risk rhabdomyosarcoma with additional risk factors (like being older than 10, having certain genetic changes, or having a tumor that wasn't fully removed or couldn't get radiation)
- Have completed initial treatment and achieved complete remission (no signs of cancer)
- Be generally healthy enough for lab tests (adequate blood counts, liver, and kidney function)
- Not have uncontrolled heart disease, bleeding disorders, or recent blood clots
- Be able to take oral medication and attend regular clinic visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
This trial tests a new combination treatment for intermediate-to-high risk rhabdomyosarcoma, a type of muscle cancer. It combines a standard chemotherapy regimen (VAC) with a vitamin A derivative called all-trans retinoic acid, which may help the chemo work better.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Hear when a new Maintenance Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.